Large-cap growth names trading below intrinsic pipeline and earnings power

Conviction: 72% · Horizon: 3Y · 2026-07-12
Eli Lilly’s $1T market cap understates its drug pipeline and franchise build-out

A trillion-dollar valuation still looks cheap versus the scale and durability of products and programs in development, implying room for multiple expansion as launches and indications compound.

Instrument Side Target Reason
LLY Long Revenue and earnings optionality from obesity, diabetes, and oncology franchises can outgrow a $1T capitalization if launch curves and margins hold.
Micron pairs extreme earnings growth with a single-digit forward multiple

Roughly 6.8x next-twelve-months earnings against a two-year earnings CAGR near 325% is a rare growth-versus-price mismatch typical of memory upcycles not yet fully priced.

Instrument Side Target Reason
MU Long Memory demand and pricing recovery can keep earnings compounding fast enough that a sub-7x NTM P/E re-rates sharply if the cycle extends beyond consensus.
NVIDIA growth is still accelerating despite scale

At very large revenue bases, reported growth rates are still picking up, which supports the view that AI infrastructure spending is not yet saturating and earnings can beat linear decay assumptions.

Instrument Side Target Reason
NVDA Long Datacenter and AI accelerator demand can sustain rising growth rates at mega-cap scale, delaying mean-reversion in multiples until supply catches demand.

Themes

The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.